The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Open accessPublished version of a preprint
Abstract
Purpose: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) after pembrolizumab treatment in melanoma patients. Experimental Design: Serum lactate dehydrogenase (LDH), routine blood count parameters, and clinical characteristics were investigated in 616 patients. Endpoints were OS and best overall response following pembrolizumab treatment. Kaplan–Meier analysis and Cox regression were applied for survival analysis. Results: Relative eosinophil count (REC) ≥1.5%, relative lymphocyte count (RLC) ≥17.5%, ≤2.5-fold elevation of LDH, and the absence of metastasis other than soft-tissue/lung were associated with favorable OS in the discovery (n = 177) and the confirmation (n = 182) cohort and had independent positive impact (all P < 0.001). Their independent role was subsequently confirmed in the validation cohort (n = 257; all P < 0.01). The number of favorable factors was strongly associated with prognosis. One-year OS probabilities of 83.9% versus 14.7% and response rates of 58.3% versus 3.3% were observed in patients with four of four compared to those with none of four favorable baseline factors present, respectively. Conclusions: High REC and RLC, low LDH, and absence of metastasis other than soft-tissue/lung are independent baseline characteristics associated with favorable OS of patients with melanoma treated with pembrolizumab. Presence of four favorable factors in combination identifies a subgroup with excellent prognosis. In contrast, patients with no favorable factors present have a poor prognosis, despite pembrolizumab, and additional treatment advances are still needed. A potential predictive impact needs to be further investigated. Clin Cancer Res; 22(22); 5487–96. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, an elevated eosinophil count prior to treatment was associated with longer overall survival in several studies.8–12”
In the citing paper
“Other pre-treatment immunological factors associated with improved treatment responses include high eosinophil and lymphocyte blood counts, an abundance of CD8+ T cells infiltrating the tumor or present at the tumor margin, and increased serum TGF-β levels in melanoma patients treated with anti-PD-1 (88, 91, 92, 109).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [109]
In the citing paper
“Importantly, it has been shown that investigating several biomarkers in combination can improve treatment predictions (109).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Blocking antibodies targeting PD-1 or its counterpart PD-L1 can prevent this form of T cell inactivation (1, 10, 18, 34) ensuring sustained antitumor activity.”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Cited by
Sorted by citations
Items 101–200 of 585
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 85
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
Voong, K. R., Feliciano, J. L., Becker, D. J., & Levy, B. P. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.48 · Cited by 84
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 82
Matsukane, R., Watanabe, H., Minami, H., Hata, K., Suetsugu, K., Tsuji, T., Masuda, S., Okamoto, I., Nakagawa, T., Ito, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79397-6 · Cited by 83
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
Lü, Z., Peng, Z., Liu, C. X., Wang, Z., Wang, Y., Jiao, X., Li, J., & Shen, L. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100041 · Cited by 81
Hamid, O., Molinero, L. L., Bolen, C. R., Sosman, J. A., Muñoz‐Couselo, E., Kluger, H. M., McDermott, D. F., Powderly, J. D., Sarkar, I., Ballinger, M. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3488 · Cited by 82
Feichtinger, R. G., & Lang, R. (2019) · Journal of Oncology · doi:10.1155/2019/2084195 · Cited by 83
Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.
Bernard-Tessier, A., Jeanville, P., Champiat, S., Lazarovici, J., Voisin, A.-L., Mateus, C., Lambotte, O., Annereau, M., & Michot, J.-M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.017 · Cited by 78
Biomarkers of response to immune checkpoint blockade in cancer treatment
Fujii, T., Naing, A., Rolfo, C. D., & Hajjar, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.010 · Cited by 77
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature
Chan, K. K., MAGRO, C. M. J., Shoushtari, A. N., Rudin, C. M., Rotemberg, V. M., Rossi, A., Lezcano, C. M., Carrino, J. A., Fernández, D., Postow, M. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0508 · Cited by 76
Self-citationTriozzi, P. L., Stirling, E. R., Song, Q., Westwood, B., Kooshki, M., Forbes, M. E., Holbrook, B. C., Cook, K. L., Alexander‐Miller, M. A., Miller, L. D., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3114 · Cited by 76
Principe, N., Kidman, J., Goh, S., Tilsed, C. M., Fisher, S. A., Fear, V. S., Forbes, C. A., Zemek, R. M., Chopra, A., Watson, M. W., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584423 · Cited by 76
Warburg effect, lactate dehydrogenase, and radio/chemo-therapy efficacy
Koukourakis, M. I., & Giatromanolaki, A. N. (2018) · International Journal of Radiation Biology · doi:10.1080/09553002.2018.1490041 · Cited by 74
The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma
Ernst, M. K., & Giubellino, A. (2022) · Biomedicines · doi:10.3390/biomedicines10040822 · Cited by 78
Targeting tumor-associated acidity in cancer immunotherapy
Lacroix, R., Rozeman, E. A., Kreutz, M. P., Renner, K., & Blank, C. U. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2195-z · Cited by 71
Self-citationCheng, J., Luo, W., Sun, C., Jin, Z., Zeng, X., Alexander, P. B., Gong, Z., Xia, X., Ding, X., Xu, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc7609 · Cited by 76
Prelaj, A., Rebuzzi, S. E., Pizzutilo, P., Bilancia, M., Montrone, M., Pesola, F., Longo, V., Bene, G. D., Lapadula, V., Cassano, F., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.11.017 · Cited by 70
van Rossum, P. S. N., Deng, W., Routman, D. M., Liu, A. Y., Cai, X., Shiraishi, Y., Peters, M., Merrell, K. W., Hallemeier, C. L., Mohan, R., et al. (2019) · Practical Radiation Oncology · doi:10.1016/j.prro.2019.07.010 · Cited by 72
Salzmann, M., Leiter, U., Loquai, C., Zimmer, L., Ugurel, S., Gutzmer, R., Thoms, K., Enk, A., & Hassel, J. C. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.029 · Cited by 70
Self-citationTallerico, R., Cristiani, C. M., Staaf, E., Garofalo, C., Sottile, R., Capone, M., de Coaña, Y. P., Madonna, G., Palella, E., Wolodarski, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1261242 · Cited by 68
Self-citationYang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 73
Ishihara, H., Tachibana, H., Takagi, T., Kondo, T., Fukuda, H., Yoshida, K., Iizuka, J., Kobayashi, H., Okumi, M., Ishida, H., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00660-6 · Cited by 67
Biomarkers to predict prognosis and response to checkpoint inhibitors
Yuasa, T., Masuda, H., Yamamoto, S., Numao, N., & Yonese, J. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1122-1 · Cited by 66
Hofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 64
Andrlová, H., Mastroianni, J., Madl, J., Kern, J. S., Melchinger, W., Dierbach, H., Wernet, F., Follo, M., Technau‐Hafsi, K., Has, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17160 · Cited by 64
Campian, J. L., Piotrowski, A., Ye, X., Hakim, F. T., Rose, J. J., Yan, X.-Y., Lu, Y., Gress, R. E., & Grossman, S. A. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2580-z · Cited by 62
Emerging immunotherapies for metastasis
Edwards, S. C., Hoevenaar, W. H. M., & Coffelt, S. B. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01160-5 · Cited by 62
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 61
Schwenck, J., Schörg, B. F., Fiz, F., Sonanini, D., Forschner, A., Eigentler, T., Weide, B., Martella, M., González-Menéndez, I., Campi, C., et al. (2019) · Theranostics · doi:10.7150/thno.35989 · Cited by 62
Self-citationBanna, G. L., Cortellini, A., Cortinovis, D. L., Tiseo, M., Aerts, J. G. J. V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100078 · Cited by 61
Biomarkers for Immune Checkpoint Inhibitors in Melanoma
Kitano, S., Nakayama, T., & Yamashita, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00270 · Cited by 63
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
Filipović, A., Miller, G., & Bolen, J. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00155 · Cited by 60
Jiang, Z., Hsu, J. L., Li, Y., Hortobágyi, G. N., & Hung, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01197 · Cited by 62
Banna, G. L., Signorelli, D., Metro, G., Galetta, D., Toma, A. D., Cantale, O., Banini, M., Friedlaender, A., Pizzutilo, P., Garassino, M. C., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-583 · Cited by 60
The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy
Fucà, G., Beninato, T., Bini, M., Mazzeo, L., Guardo, L. D., Cimminiello, C., Randon, G., Apollonio, G., Bisogno, I., Vecchio, M. D., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00819-0 · Cited by 60
Scanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722022 · Cited by 59
Park, W., Kwon, D., Saravia, D., Desai, A. J., Vargas, F., Dinali, M. E., Warsch, J. R. L., Elias, R. M., Chae, Y. K., Kim, D. W., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.12.007 · Cited by 59
Kunert, A., Basak, E. A., Hurkmans, D. P., Balcioglu, H. E., Klaver, Y., van Brakel, M., Oostvogels, A. A. M., Lamers, C. H. J., Bins, S., Koolen, S. L. W., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0608-y · Cited by 59
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 59
Suzuki, K., Terakawa, T., Furukawa, J., Harada, K., Hinata, N., Nakano, Y., & Fujisawa, M. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01528-5 · Cited by 56
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Tunger, A., Sommer, U. J., Wehner, R., Kubasch, A. S., Grimm, M., Bachmann, M. P., Platzbecker, U., Bornhäuser, M., Baretton, G. B., & Schmitz, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101534 · Cited by 53
Castello, A., Toschi, L., Rossi, S., Mazziotti, E., & Lopci, E. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03150-9 · Cited by 53
Yao, L., Jia, G., Lu, L., Bao, Y., & Ma, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106628 · Cited by 54
Eosinophils in the Tumor Microenvironment
Mattei, F., Andreone, S., Marone, G., Gambardella, A. R., Loffredo, S., Varricchi, G., & Schiavoni, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_1 · Cited by 53
Agulló-Ortuño, M. T., Gómez-Martín, Ó., Ponce, S., Iglesias, L., Ojeda, L., Ferrer, I., García‐Ruíz, I., Paz-Ares, L. G., & Pardo, V. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.08.006 · Cited by 53
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Kreft, S., Gesierich, A., Eigentler, T., Franklin, C., Valpione, S., Ugurel, S., Utikal, J. S., Haferkamp, S., Blank, C. U., Larkin, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.05.015 · Cited by 51
Self-citationFujisawa, Y., Yoshino, K., Otsuka, A., Funakoshi, T., Fujimura, T., Yamamoto, Y., Hata, H., Tanaka, R., Yamaguchi, K., Nonomura, Y., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16427 · Cited by 50
Sachpekidis, C., Kopp‐Schneider, A., Hakim-Meibodi, L. E., Dimitrakopoulou‐Strauss, A., & Hassel, J. C. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000541 · Cited by 50
Self-citationHurkmans, D. P., Jensen, C., Koolen, S. L. W., Aerts, J., Karsdal, M. A., Mathijssen, R. H. J., & Willumsen, N. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001193 · Cited by 49
Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
Wang, D. Y., Eroglu, Z., Özgün, A., Leger, P. D., Zhao, S., Ye, F., Luke, J. J., Joseph, R. W., Haq, R., Ott, P. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0287 · Cited by 52
Wang, X., Zhang, B., Chen, X., Mo, H., Wu, D., Lan, B., Li, Q., Xu, B., & Huang, J. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13083 · Cited by 49
Novel Biomarkers for Personalized Cancer Immunotherapy
Shindo, Y., Hazama, S., Tsunedomi, R., Suzuki, N., & Nagano, H. (2019) · Cancers · doi:10.3390/cancers11091223 · Cited by 49
Juliá, E. P., Mandó, P., Rizzo, M., Cueto, G. R., Tsou, F., Luca, R., Pupareli, C. S., Bravo, A., Astorino, W., Mordoh, J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02391-z · Cited by 50
Precision medicine driven by cancer systems biology
Filipp, F. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9662-4 · Cited by 52
Eosinophils and Lung Cancer: From Bench to Bedside
Sibille, A., Corhay, J.-L., Louis, R. E., Ninane, V., Jérusalem, G., & Duysinx, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095066 · Cited by 48
Combination Immunotherapy Development in Melanoma
Eggermont, A. M. M., Crittenden, M. R., & Wargo, J. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201131 · Cited by 47
Lymphopenia and intratumoral lymphocytic balance in the era of cancer immuno-radiotherapy
Koukourakis, M. I., & Giatromanolaki, A. N. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103226 · Cited by 46
Paidi, S. K., Troncoso, J. R., Raj, P., Diaz, P. M., Ivers, J. D., Lee, D. E., Avaritt, N. L., Gies, A. J., Quick, C. M., Byrum, S. D., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1438 · Cited by 46
Emerging Biomarkers in Cutaneous Melanoma
Eisenstein, A. S., Gonzalez, E. C., Raghunathan, R., Xu, X., Wu, M., McLean, E. O., McGee, J. S., Ryu, B., & Alani, R. M. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0318-z · Cited by 48
What Are the Biomarkers for Immunotherapy in SCLC?
Longo, V., Catino, A., Montrone, M., Pizzutilo, P., Annese, T., Pesola, F., Marech, I., Cassiano, S., Ribatti, D., & Galetta, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011123 · Cited by 46
Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives
Malissen, N., & Grob, J. (2018) · Drugs · doi:10.1007/s40265-018-0945-z · Cited by 46
Benítez, J. C., Recondo, G., Rassy, E., & Mezquita, L. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03250-1 · Cited by 45
Failing, J. J., Yan, Y., Porrata, L. F., & Markovic, S. N. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000404 · Cited by 44
Jiang, M., Peng, W., Pu, X., Chen, B., Li, J., Xu, F., Liu, L.-Y. D., Xu, L., Xu, Y., Cao, J., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00913 · Cited by 45
Tenuta, M., Gelibter, A. J., Pandozzi, C., Sirgiovanni, G., Campolo, F., Venneri, M. A., Caponnetto, S., Cortesi, E., Marchetti, P., Isidori, A. M., et al. (2021) · Cancers · doi:10.3390/cancers13246355 · Cited by 44
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 43
Mitsuhashi, A., & Okuma, Y. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1827-7 · Cited by 43
Ma, G., Li, C., Zhang, Z., Liang, Y., Liang, Z., Chen, Y., Wang, L., Li, D., Zeng, M., Shan, W., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.697894 · Cited by 45
Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma
Chasseuil, E., Saint-Jean, M., Chasseuil, H., Peuvrel, L., Quereux, G., Nguyen, J., Gaultier, A., Varey, É., Khammari, A., & Dréno, B. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-2872 · Cited by 43
Zhuo, M., Chen, H., Zhang, T., Yang, X., Zhong, J., Wang, Y., An, T., Wu, M., Wang, Z., Huang, J., et al. (2018) · Cancer Biomarkers · doi:10.3233/cbm-171089 · Cited by 42
Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer
Satomi, N., Shimomura, A., Matsuzaki, J., Yamamoto, Y., Kawauchi, J., Takizawa, S., Aoki, Y., Sakamoto, H., Kato, K., Shimizu, C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222024 · Cited by 42
Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy
Xu, J., Zhao, J., Wang, J., Sun, C., & Zhu, X. (2021) · Medicine · doi:10.1097/md.0000000000025318 · Cited by 42
Wen, X., Ding, Y., Li, J., Zhao, J., Peng, R., Li, D., Zhu, B., Wang, Y., Zhang, X., & Zhang, X. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1989-8 · Cited by 41
Ferrucci, P. F., Gandini, S., Cocorocchio, E., Pala, L., Baldini, F., Mosconi, M., Cappellini, G. C. A., Albertazzi, E., & Martinoli, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19748 · Cited by 41
Current and emerging systemic therapies for cutaneous metastatic melanoma
Mason, R., Au, L., Garces, A. I., & Larkin, J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601700 · Cited by 45
Schouwenburg, M. G., Suijkerbuijk, K. P. M., Koornstra, R. H. T., Jochems, A., van Zeijl, M. C. T., van den Eertwegh, A. J. M., Haanen, J. B. A. G., Aarts, M. J. B., van Akkooi, A. C. J., van den Berkmortel, F. W. P. J., et al. (2019) · Cancers · doi:10.3390/cancers11121940 · Cited by 40
Self-citationKrishnan, T., Tomita, Y., & Roberts‐Thomson, R. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0070 · Cited by 40
Greene, E., Finak, G., D’Amico, L., Bhardwaj, N., Church, C. D., Morishima, C., Ramchurren, N., Taube, J. M., Nghiem, P., Cheever, M. A., et al. (2021) · Patterns · doi:10.1016/j.patter.2021.100372 · Cited by 40
Sun, R., Champiat, S., Dercle, L., Aspeslagh, S., Álvarez, E. C., Limkin, E. J., Baldini, C., Postel-Vinay, S. C., Hollebecque, A., Massard, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.033 · Cited by 39
Hasegawa, T., Yanagitani, N., Utsumi, H., Wakui, H., Sakamoto, H., Tozuka, T., Yoshida, H., Amino, Y., Uematsu, S., YOSHIZAWA, T., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13902 · Cited by 39
Li, Y., Meng, Y., Sun, H., Ye, L., Zeng, F., Chen, X., & Deng, G. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000392 · Cited by 39
Capone, M., Fratangelo, F., Giannarelli, D., Sorrentino, C., Turiello, R., Zanotta, S., Galati, D., Madonna, G., Tuffanelli, M., Scarpato, L., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02285-0 · Cited by 38
Self-citationFacchinetti, F., Veneziani, M., Buti, S., Gelsomino, F., Squadrilli, A., Bordi, P., Bersanelli, M., Cosenza, A., Ferri, L., Rapacchi, E., et al. (2018) · Immunotherapy · doi:10.2217/imt-2017-0175 · Cited by 37
Park, W., & Lopes, G. D. L., Jr. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.003 · Cited by 37
Ghebeh, H., Elshenawy, M. A., Alsayed, A., & Al‐Tweigeri, T. (2022) · Immunotherapy · doi:10.2217/imt-2021-0149 · Cited by 37
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
Pabst, L., Lopes, S., Bertrand, B., Creusot, Q., Kotovskaya, M., Pencreach, E., Beau‐Faller, M., & Mascaux, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087577 · Cited by 37
Blank, C. U., Larkin, J., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.04.007 · Cited by 36
Self-citationTietze, J. K., Forschner, A., Loquai, C., Mitzel-Rink, H., Zimmer, L., Meiß, F., Rafei-Shamsabadi, D. A., Utikal, J. S., Bergmann, M., Meier, F. E., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26149 · Cited by 38
Self-citationFirst-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
Schilling, B., Martens, A., Foppen, M. H. G., Gebhardt, C., Hassel, J. C., Rozeman, E. A., Gesierich, A., Gutzmer, R., Kähler, K. C., Livingstone, E., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02311-1 · Cited by 36
Self-citationTargeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
Bai, X. L., & Flaherty, K. T. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19394 · Cited by 38
Awada, G., Jansen, Y. J. L., Schwarze, J. K., Tijtgat, J., Hellinckx, L., Gondry, O., Vermeulen, S., Warren, S. E., Schats, K., van Dam, P., et al. (2021) · Cancers · doi:10.3390/cancers13020168 · Cited by 36
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 38
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
Masucci, G. V., Cesano, A., Eggermont, A. M. M., Fox, B. A., Wang, E., Marincola, F. M., Ciliberto, G., Dobbin, K. K., Puzanov, I. J., Taube, J. M., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1325-2 · Cited by 36
Self-citationHarnessing myeloid cells in cancer
Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 35
Forschner, A., Olthof, S.-C., Gückel, B., Martus, P., Vach, W., la Fougère, C. J., Nikolaou, K., Keim, U., Eigentler, T., Garbe, C., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3674-8 · Cited by 35
Self-citationCortese, N., Capretti, G. L., Barbagallo, M., Rigamonti, A., Takis, P. G., Castino, G. F., Vignali, D., Maggi, G., Gavazzi, F., Ridolfi, C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0403 · Cited by 35
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
Ma, Y., Ma, X., Wang, J., Wu, S., Wang, J., & Cao, B. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02695-y · Cited by 34
Weide, B., Martens, A., Wistuba‐Hamprecht, K., Zelba, H., Maier, L., Lipp, H., Klumpp, B. D., Soffel, D., Eigentler, T., & Garbe, C. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1944-0 · Cited by 34
Self-citation
Metadata
- Authors
- Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., Brenner, N., Kähler, K., Heinzerling, L., Gutzmer, R., Bender, A., Gebhardt, C., Romano, E., Meier, F., Martus, P., Maio, M., Blank, C., Schadendorf, D., Dummer, R., Ascierto, P. A., Hospers, G., Garbe, C., & Wolchok, J. D.
- Affiliations
- Universitätsklinikum Tübingen (DE)
- Heidelberg University (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Memorial Sloan Kettering Cancer Center (US)
- University Medical Center Groningen (NL)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- 10Department of Dermatology, University of Zürich, Zürich, Switzerland.
- 12Division of Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy.
- University Hospital Cologne (DE)
- University Hospital Schleswig-Holstein (DE)
- Universitätsklinikum Erlangen (DE)
- Medizinische Hochschule Hannover (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- German Cancer Research Center (DE)
- Institut Curie (FR)
- University of Tübingen (DE)
- University of Siena (IT)
- The Netherlands Cancer Institute (NL)
- University of Zurich (CH)
- Corresponding author
- Weide, Benjamin
- ORCID
- Weide, Benjamin
- Hassel, Jessica C.
- Berking, Carola
- Postow, Michael A.
- Bisschop, Kees
- Simeone, Ester
- Schilling, Bastian
- Brenner, Nicole
- Kähler, Katharina
- Heinzerling, Lucie
- Gutzmer, Ralf
- Gebhardt, Christoffer
- Romano, Emanuela
- Meier, Friedegund
- Martus, Peter
- Maio, Michele
- Blank, Christian
- Schadendorf, Dirk
- Dummer, Reinhard
- Ascierto, Paolo A.
- Hospers, Geke
- Garbe, Claus
- Wolchok, Jedd D.
- Venue
- Clinical Cancer Research
- Published
- 2016-11-14
- Volume
- 22
- Issue
- 22
- Pages
- 5487-5496
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC5572569
- OpenAlex
- W2397854274
- Semantic Scholar
- b5a9c4e2d6333e54d55ec140895bb53cebb851f9
- Cited by
- 589
- References
- 44
- Citations by year
- 2026: 17 · 2025: 38 · 2024: 31 · 2023: 46 · 2022: 57 · 2021: 91 · 2020: 86 · 2019: 77 · 2018: 72 · 2017: 59 · 2016: 14
- FWCI
- 39.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, pembrolizumab, immune checkpoint blockade, prognostic factors, overall survival, lactate dehydrogenase, eosinophil count, lymphocyte count, metastasis, best overall response, predictive biomarkers
- MeSH terms
- Aged, Antibodies, Monoclonal, Female, Humans, L-Lactate Dehydrogenase, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Biomarkers, Tumor, Cohort Studies, Survival Analysis, Treatment Outcome, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
